The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

The U.S. Centers for Disease Control and Prevention's vaccine experts are expected to vote on expanding access to respiratory ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

The 15-member panel typically makes recommendations to the director of the CDC on how vaccines should be used. But in a break ...

After decades of fits and starts, scientists finally got the world’s first vaccines against respiratory syncytial virus ...

CDC advisors recommended this week that the age at which some patients can get vaccinated against respiratory syncytial virus be lowered to 50 years old. The Advisory Committee on Immunization ...

Although we can’t control what others chose to do about handwashing and social distancing, we can decide to protect our infants with vaccination.